Marie AUDRAIN

Dr. Marie AUDRAIN


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Clinical Immunology
Verified
Journal Article
Closed access
MAMarie AUDRAIN
Marie AUDRAIN
CTCaroline Thomas
Caroline Thomas
SMSophie Mirallie
Sophie Mirallie
NBNathalie Bourgeois
Nathalie Bourgeois
VSVéronique Sebille
Véronique Sebille
AFAlain Fischer
Alain Fischer

24 September 2018 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
MAMarie AUDRAIN
Marie AUDRAIN
ALAlexandra J. C. Léger
Alexandra J. C. Léger
CHCaroline A. F. Hémont
Caroline A. F. Hémont
SMSophie M. Mirallié
Sophie M. Mirallié
DCDavid Cheillan
David Cheillan
CTCaroline J. C. Thomas
Caroline J. C. Thomas

19 July 2011 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MAMarie AUDRAIN
Marie AUDRAIN
JMJérôme Martin
Jérôme Martin
PFPatricia Fromont
Patricia Fromont
NPNolwen Prié
Nolwen Prié
CTCaroline Thomas
Caroline Thomas
EMEt Jean‐Yves Muller
Et Jean‐Yves Muller

16 September 2003 in Rheumatology
Verified
Journal Article
Open access
PDF file
MAMarie AUDRAIN
Marie AUDRAIN
FCFrançoise Colonna
Françoise Colonna
FMFlorent Morio
Florent Morio
MHMohamed A. Hamidou
Mohamed A. Hamidou
JMJean-Yves Muller
Jean-Yves Muller
Objective. To estimate the performance characteristics of 10 commercial kits and one in-house kit for the detection and quantification of anticardiolipin (aCL) (six kits) and anti-β2glycoprotein 1 (anti-β2GP1) (five kits) antibodies, and to evaluate the degree of variability between these different kits. Methods. We determined the presence of aCL and anti-β2GP1 IgG and IgM antibodies in 67 sera from 62 patients and reviewed the data separately. Each serum sample was tested with six commercial aCL determination kits and with four commercial and one in-house anti-β2GP1 determination kit. We then analysed the operating characteristics of each kit (sensitivity, specificity, positive and negative predictive values) and we analysed the absolute and 2×2 agreements. Results. The 62 patients included had primary antiphospholipid syndrome (APS) in 10 cases, secondary APS for eight, systemic lupus (SLE) for 23 and other diagnoses for the remaining 21. Operating characteristics differed from one kit to another. Good agreement was found using sensitive aCL determination kit and specific anti-β2GP1 determination kit. Agreement between kits was medium for IgG aCL. 2×2 concordance studies showed a group of three aCL kits which were quite homogenous and showed that all anti-β2GP1 kits formed quite a homogenous group. Conclusion. A high degree of variability still persists for aCL antibody determination posing the question of the qualification of commercial or in-house kits and the question of standardization of results. A better concordance is found for high positive results. Good agreement exists for anti-β2GP1 kits. aCL determination is still needed and should be complemented by anti-β2GP1 determination.

Verified
Journal Article
Open access
PDF file
MAMarie AUDRAIN
Marie AUDRAIN
CTCaroline Thomas
Caroline Thomas
After it was demonstrated in 2005 that T cell receptor excision circle (TREC) quantification for dried blood spot (DBS) samples on Guthrie cards is an effective means of SCID screening and following several pilot studies, the practice was formally recommended in the US in 2010. More and more countries have adopted it since then. In France, before the health authorities could recommend adding SCID to the list of five diseases that were routinely screened for, feasibility and cost-effectiveness studies had to be conducted with a sufficiently large cohort of neonates. We carried out three such studies: The first sought to verify the effectiveness of the assay. The second, DEPISTREC, evaluated the feasibility of universal SCID screening in France and assessed the clinical benefit and economic advantage it would provide. Through the third study, NeoSKID, still under way and to continue until recommendations are issued, we have been offering SCID screening in the Pays de la Loire region of France. This review briefly describes routine newborn screening (NBS) and management of primary immunodeficiency diseases (PIDs) in France, and then considers the lessons from our studies and the status of SCID screening implementation within the country.

3 July 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
JWJosiane Warszawski
Josiane Warszawski
CTCaroline Thomas
Caroline Thomas
ODOlivia Dialla
Olivia Dialla
VGValérie Garrait
Valérie Garrait
CDCatherine Dollfus
Catherine Dollfus
MBMaud Brossard
Maud Brossard